J C Kuo
Overview
Explore the profile of J C Kuo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuo J, Graham D, Salvarrey A, Kassam F, Le L, Shepherd F, et al.
Curr Oncol
. 2020 Jun;
27(2):e156-e162.
PMID: 32489264
Introduction: Improving health-related quality of life (hrqol) is a key goal of systemic therapy in advanced lung cancer, although routine assessment remains challenging. We analyzed the impact of a real-time...
2.
Kuo J, Ockerman H
J Food Prot
. 2019 Apr;
48(2):142-146.
PMID: 30934527
Both pre- and post-rigor beef semimembranosus muscles were ground with salt (0, 2 and 4%) and then subdivided into two treatment groups (freezing and freeze drying) and evaluated during storage...
3.
Kuo J, Ockerman H
J Food Prot
. 2019 Mar;
47(4):316-320.
PMID: 30921970
The water-holding capacity (WHC) of frozen and reconstituted lyophilized (freeze-dried) beef (both pre- and post-rigor) increased (P<0.05) with the increase in salt levels (0, 2 and 4%). Freeze-dried and reconstituted...
4.
5.
Chang Y, Kuo J, Chen Y
Commun Agric Appl Biol Sci
. 2014 Aug;
78(4):73-6.
PMID: 25141628
No abstract available.
6.
Kuo J, Parakh S, Yip D
J Clin Pharm Ther
. 2014 Apr;
39(4):446-8.
PMID: 24707992
What Is Known And Objective: Regorafenib improves progression-free survival as a late-line treatment for patients with metastatic gastrointestinal stromal tumour (GIST). As a multitargeted tyrosine kinase inhibitor (TKI), the expected...
7.
Kuo J, Hawkins C, Yip D
Intern Med J
. 2014 Jan;
44(5):442-9.
PMID: 24393214
Background: Hypersensitivity reactions (HSR) to chemotherapeutic agents and monoclonal antibodies are common and may limit further therapeutic options. Drug desensitisation aims to induce a temporary clinical unresponsiveness to drug antigens...
8.
Pan C, Hwang C, Kuo J, Shieh J, Wu K
Opt Lett
. 2009 Oct;
17(21):1547.
PMID: 19798243
No abstract available.
9.
Pan C, Hwang C, Kuo J, Shieh J, Wu K
Opt Lett
. 2009 Oct;
17(20):1444.
PMID: 19798208
No abstract available.
10.
Pan C, Kuo J, Hwang C, Shieh J, Lai Y, Chang C, et al.
Opt Lett
. 2009 Oct;
17(14):994-6.
PMID: 19794698
No abstract available.